The results suggested that deletion of USP11 could lead to increased apoptosis of HCC cells compared with control cells (expressing USP11) and that USP11‐deleted HepG2 cells were more sensitive to sorafenib treatment. The gene discussed is USP11; the disease is hepatocellular carcinoma.